Jnking Atherosclerosis

Science's STKE  30 Nov 2004:
Vol. 2004, Issue 261, pp. tw430
DOI: 10.1126/stke.2612004tw430

Atherosclerosis is the most common cardiovascular disease in Europe and North America. The c-Jun N-terminal kinase (JNK) family is implicated in atherogenesis. Ricci et al. addressed the function of JNK in atherogenesis, using atherosclerosis-prone apolipoprotein E (ApoE)-deficient mice simultaneously lacking either JNK1 or JNK2. JNK2 deletion strikingly reduced plaque formation in ApoE-deficient mice. However, deletion of JNK1 revealed only a slight effect on atheroma formation. Pharmacological inhibition of overall JNK activity substantially suppressed atherosclerosis in ApoE-deficient mice. Specific inhibition of JNK2 activity may thus represent a therapeutic approach to ameliorate atherosclerosis.

R. Ricci, G. Sumara, I. Sumara, I. Rozenberg, M. Kurrer, A. Akhmedov, M. Hersberger, U. Eriksson, F. R. Eberli, B. Becher, J. Borén, M. Chen, M. I. Cybulsky, K. J. Moore, M. W. Freeman, E. F. Wagner, C. M. Matter, T. F. Lüscher, Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306, 1558-1561 (2004). [Abstract] [Full Text]